Figure 4
Human cervical cancer cells viability, migration and proliferation. ME180 cells (3 × 104/ml) were treated with negative shRNA, MCP shRNA, DAF shRNA and MCP shRNA+ DAF shRNA respectively in this experiment. (A): The ME180 cells viability was detected via WST-1 assay. Sample absorbance was analyzed using a bichromatic ELISA reader at 450 nm. **p < 0.01 versus MCP shRNA+ DAF shRNA, # p < 0.05 versus MCP shRNA+ DAF shRNA. (B): The migration of ME180 cells was measured by Transwell assay. The migrated cells were counted microscopically (400×) in five different fields per filter. **p < 0.01 versus MCP shRNA+ DAF shRNA, # p < 0.05 versus MCP shRNA+ DAF shRNA. (C) to observe the measuring 3H-thymidine incorporated into DNA over the last 18 h of the final incubation. Results were mean ± SD from 3 independent experiments. **p < 0.01 versus MCP shRNA+ DAF shRNA, # p < 0.05 versus MCP shRNA+ DAF shRNA.